This content is Free Access.
1Department of Medicine and the Gregory Fleming James Cystic Fibrosis Center,University of Alabama at Birmingham, 2Department of Pulmonology and Tuberculosis,University Medical Center Utrecht, 3Center for Experimental Medicine,Queens University, Northern Ireland, 4Hadassah Hebrew University Medical Center, Jerusalem, 5Centro Fibrosi Cistica,Azienda Ospedaliera Universitaria Integrata, 6Service de Pneumologie et Allergologie Pédiatriques and Center de Ressources et de Compétence de la Mucoviscidose,Hôpital Necker Enfants Malades, 7INSERM U 1151,Institut Necker Enfants Malades
Chapitres
- 00:04Titre
- 01:01Materials Setup
- 02:19Measurement Electrode Placement
- 04:35Basal Potential Difference (PD) Measurement
- 06:02Nasal Membrane Transepithelial Potential Difference (NPD) Tracing Sequential Perfusions
- 07:42Results: Representative CF and Healthy Subject Tracings
- 08:57Conclusion
Here, we present a standardized protocol to measure the nasal potential difference (NPD). Cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC) function are evaluated by the change in the voltage across the nasal epithelium after superfusion of solutions that modify ion channel activity, providing an outcome measure.
